PT - JOURNAL ARTICLE AU - Jennifer A. Frontera AU - Allal Boutajangout AU - Arjun V. Masurkar AU - Rebecca A. Betensky AU - Yulin Ge AU - Alok Vedvyas AU - Ludovic Debure AU - Andre Moreira AU - Ariane Lewis AU - Joshua Huang AU - Sujata Thawani AU - Laura Balcer AU - Steven Galetta AU - Thomas Wisniewski TI - Elevation of Neurodegenerative Serum Biomarkers among Hospitalized COVID-19 Patients AID - 10.1101/2021.09.01.21262985 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.01.21262985 4099 - http://medrxiv.org/content/early/2021/09/05/2021.09.01.21262985.short 4100 - http://medrxiv.org/content/early/2021/09/05/2021.09.01.21262985.full AB - INTRODUCTION Older adults hospitalized with COVID-19 are susceptible to neurological complications, particularly encephalopathy, which may reflect age-related neurodegenerative processes.METHODS Serum total tau, ptau-181, GFAP, NFL, UCHL1, and amyloid-beta(Aβ-40,42) were measured in hospitalized COVID-19 patients without a history of dementia, and compared among patients with or without encephalopathy, in-hospital death versus survival, and discharge home versus other dispositions using multivariable Cox proportional hazards regression analyses.RESULTS Among 251 patients, admission serum ptau-181 and UCHL1 were significantly elevated in patients with encephalopathy (both P<0.05) and total tau, GFAP, and NFL were significantly lower in those discharged home(all P<0.05). These markers correlated significantly with severity of COVID illness. NFL, GFAP and UCH-L1 were significantly higher in hospitalized COVID patients than in non-COVID controls with mild cognitive impairment or Alzheimer’s disease(AD).DISCUSSION Age-related neurodegenerative biomarkers were elevated to levels observed in AD and associated with encephalopathy and worse outcomes among hospitalized COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: NIH/NIA (Wisniewski) COVID-19 administrative supplement 3P30AG066512-01 Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NYU Langone Health IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonable request